Skip to main content
    E

    Eterna Therapeutics Inc (ERNA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.17
    +0.06 (+2.84%)

    Market Cap: $3.44M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(11/22)
    Avg Surprise
    -369.84%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-3.84
    Range$-3.84 - $-3.84
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$-3.840.0%
    30d ago$-3.840.0%
    7d ago$-3.840.0%
    Current$-3.84
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Sep 26EST
    		-$-3.84---
    Jun 26
    Reported Aug 6
    		$-3.40$-3.30-3.03%Miss-457.4%
    Mar 26
    Reported May 11
    		$-6.95$-1.95-256.41%Miss-200.9%
    Dec 25
    Reported Mar 13
    		$-4.81N/AN/ABeat-3104.3%
    Sep 25
    Reported Nov 7
    		$-0.15$0.00N/AMiss+100.0%
    Jun 25
    Reported Aug 13
    		$-0.61$0.00N/AMiss+99.8%
    Mar 25
    Reported May 7
    		$-2.31$0.00N/AMiss+99.5%
    Dec 24
    Reported Mar 13
    		$-0.15$0.00N/AMiss+100.0%
    Sep 24
    Reported Nov 12
    		$-1844.09$0.00N/ABeat-178331.1%
    Jun 24
    Reported Aug 13
    		$-383.80$0.00N/ABeat-44968.5%
    Mar 24
    Reported May 13
    		$-460.74$0.00N/ABeat-37056.8%
    Dec 23
    Reported Mar 13
    		$-427.06$0.00N/ABeat-34340.0%
    Sep 23
    Reported Nov 13
    		$-1.03N/AN/ABeat+99.9%
    Jun 23
    Reported Aug 11
    		$-0.85N/AN/ABeat+99.8%
    Mar 23
    Reported May 11
    		$-1.24$-0.14-785.71%Miss+61.3%
    Dec 22
    Reported Mar 20
    		$-1.24$-0.14-785.71%Miss+61.3%
    Sep 22
    Reported Nov 14
    		$-933.75$-825.00-13.18%Miss+92.7%
    Jun 22
    Reported Jul 1
    		$-450.00N/A+53.85%Beat-187400.0%
    Mar 22
    Reported Apr 15
    		$-3.20N/A+99.66%Beat-16100.0%
    Dec 21
    Reported Dec 31
    		$-3.20N/A+99.66%Beat-3300.0%
    Sep 21
    Reported Nov 9
    		$-12749.99$-600.00-2025.00%Beat-63750050.0%
    Jun 21
    Reported Aug 13
    		$-0.24N/AN/ABeat-1300.0%
    Mar 21
    Reported May 17
    		$0.02N/AN/ABeat+0.0%
    Dec 20
    Reported Mar 11
    		$0.10N/AN/ABeat+122.2%
    Sep 20
    Reported Nov 11
    		$0.02N/AN/ABeat+116.7%
    Jun 20
    Reported Aug 7
    		$0.02N/AN/ABeat+166.7%
    Mar 20
    Reported May 19
    		$0.02N/AN/ABeat+118.2%
    Dec 19
    Reported Mar 19
    		$-0.45$0.01-4600.00%Miss-110.2%
    Sep 19
    Reported Oct 10
    		$-0.12$-0.03-300.00%Miss-103.8%
    Jun 19
    Reported Aug 9
    		$-0.03$-0.03+0.00%Beat+98.5%
    Mar 19
    Reported May 13
    		$-0.11$0.20-155.00%Miss+98.3%
    Dec 18
    Reported Mar 20
    		$4.40$6.00-26.67%Miss+144.0%
    Sep 18
    Reported Nov 7
    		$3.20$-1.60+300.00%Beat+214.3%
    Jun 18
    Reported Aug 2
    		$-2.00N/A+78.26%Beat+28.6%
    Mar 18
    Reported May 9
    		$-6.40$-10.80+40.74%Beat-300.0%
    Dec 17
    Reported Mar 6
    		$-10.00$-5.60-78.57%Miss-13.6%
    Sep 17
    Reported Nov 7
    		$-2.80N/A+66.67%Beat-
    Jun 17
    Reported Aug 2
    		$-2.80N/A+80.00%Beat-
    Mar 17
    Reported May 3
    		$-1.60N/A+89.74%Beat-
    Dec 16
    Reported Mar 6
    		$-8.80$-7.60-15.79%Miss-

    Key Metrics

    Valuation
    P/E Ratio-0.14EV/EBITDAN/A
    Price/FCF-0.29xFCF Yield-345.84%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-320.70%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio2.01xQuick Ratio2.01x
    Trading Statistics
    Beta2.65Avg Volume65.06K
    52-Week High$48.0052-Week Low$2.01

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.39
    SMA 20$2.95
    SMA 50$3.81
    SMA 200$8.96
    EMA 10$2.44
    EMA 20$2.85
    EMA 50$3.71
    EMA 200$11.79

    MACD

    Line: -0.52Signal: -0.47Hist: -0.04

    ADX

    ADX: 26.0+DI: 13.4-DI: 28.6

    Aroon & PSAR

    Aroon Up12.0
    Aroon Down96.0
    PSAR$2.34

    Bollinger Bands

    Upper Band$4.24
    Lower Band$1.66
    %B Position8741%(Upper)
    Band Width0.20

    RSI (14-Day)

    Oversold
    25.3

    Momentum Oscillators

    Stoch %K6.5
    Stoch %D6.8
    Williams %R-90.9
    ROC (10d)-26.7%
    Momentum-0.79
    CCI (20d)-97.0
    MFI (14d)20.4

    Volatility Measures

    ATR (14d)$0.34(15.7%)
    StdDev (20d)0.64
    Hist Vol90.9%(High)

    Volume Flow

    VWAP$2.15
    OBV352.5M
    AD Line183.6B
    CMF (20d)0.356

    Volume Metrics

    Avg Vol (20d)68.8K
    Vol Ratio0.1x(Low)
    VWMA (20d)$2.58

    Pivot Points

    R3$2.39
    R2$2.29
    R1$2.20
    Pivot Point$2.11
    S1$2.02
    S2$1.92
    S3$1.83

    Advanced Oscillators

    TSI-48.45
    Ultimate Osc50.0
    KST-399.04

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$1,000$487,000$47,000$47,000$17,000$51,000
    Cost of Revenue$0$0$69,000$0$0$0$-541,000$-60,000$95,000$61,000$66,000$120,000
    Gross Profit$0$0$-69,000$0$0$0$1,000$547,000$-48,000$-14,000$-49,000$-69,000
    Operating Expenses$4.10M$5.59M$2.10M$1.99M$2.50M$2.73M$2.70M$2.81M$4.88M$5.77M$5.72M$5.44M
    R&D$2.79M$1.92M$676,000$1.03M$1.14M$1.31M$1.16M$1.00M$987,000$1.46M$1.36M$1.39M
    SG&A$1.31M$1.63M$1.42M$958,000$1.36M$1.42M$1.54M$3.38M$3.90M$4.32M$4.36M$4.05M
    Operating Income$-4,104,000$-5,590,000$-2,095,000$-1,993,000$-2,501,000$-2,730,000$-2,697,000$-2,259,000$-4,931,000$-5,787,000$-5,765,000$-5,505,000
    Interest Income$55,000$44,000$20,000$31,000$0$5,000$-3,234,000$-1,686,000$-797,000$-786,000$-388,000$-113,000
    Interest Expense$-41,000$0$0$-734,000$0$5.46M$3.05M$22.44M$595,000$856,000$392,000$0
    Income Before Tax$-4,009,000$-5,546,000$-1,565,000$-1,234,000$-3,136,000$-8,194,000$-5,748,000$-26,592,000$-5,526,000$-6,643,000$-6,157,000$-5,599,000
    Income Tax Expense$0$-40,000$-62,000$6,000$3,000$8,000$11,000$12,000$3,000$4,000$-4,000$-8,000
    Net Income$-4,009,000$-5,506,000$-1,503,000$-1,240,000$-3,139,000$-8,202,000$-5,759,000$-26,604,000$-5,529,000$-6,647,000$-6,153,000$-5,591,000
    EBITDA$-4,060,000$-5,504,000$-1,547,000$-1,929,000$-3,081,000$-8,130,000$665,000$-786,000$-3,677,000$-4,871,000$-5,037,000$-4,917,000
    EBIT$-4,104,000$-5,590,000$-1,616,000$-1,999,000$-3,136,000$-8,199,000$-2,514,000$-2,466,000$-4,729,000$-5,857,000$-5,769,000$-5,486,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ERNA

    News

    Ernexa Therapeutics posts investor presentation under Regulation FD, available on investor site

    Ernexa Therapeutics (ERNA) has posted an investor presentation under Regulation FD on its investor website. This disclosure was made via a Form 8-K filing on October 15, 2026...

    TradingView•10/15/26•Neutral

    Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series on October 15, Highlighting ERNA-101 Development

    Ernexa Therapeutics will host a live video webcast on October 15, 2026, at 4:00 PM ET, featuring key executives including CEO Sanjeev Luther and CSO Dr. Robert Pierce. The event will focus on the company's lead...

    Quiver Quantitative•10/12/26•Somewhat-Bullish

    Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

    Ernexa Therapeutics announced its participation in the Virtual Investor Closing Bell Series on October 15, 2026...

    GlobeNewswire•10/12/26•Somewhat-Bullish

    Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk

    Ernexa Therapeutics announced that preclinical data for its lead oncology program, ERNA-101, has been selected for a Flash Talk presentation at the Nature Conferences’ Next-Generation Cancer Therapeutics meeting....

    GlobeNewswire•10/6/26•Bullish

    Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk at Next-Generation Cancer Therapeutics Meeting for Preclinical Ovarian Cancer Data

    Ernexa Therapeutics announced that its lead oncology therapy, ERNA-101, will be presented at the Next-Generation Cancer Therapeutics meeting. Preclinical data shows ERNA-101's effectiveness in enhancing immune responses...

    Quiver Quantitative•10/6/26•Bullish

    ERNA Valuation and Fair Value

    P/E
    -0.1x
    P/FCF
    -0.3x
    P/B
    0.8x
    See GNG's fair value

    ERNA Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -320.7%
    FCF yield
    -345.8%

    ERNA Competitors

    CompanyTicker
    Akanda CorpAKAN
    Eocene Ltd.EOCN
    NanoVibronix IncNAOV
    Sunshine Biopharma IncSBFM
    PharmaCyte Biotech IncPMCB
    Mainz Biomed BVMYNZ
    cbdMD IncYCBD
    IO Biotech IncIOBT

    Sector: Healthcare

    ERNA Bull Case vs Bear Case

    Bear case

    • ERNA beat EPS estimates in 0.0% of its last 8 reported quarters.
    • ERNA's quarterly revenue changed -94.1% year over year.

    ERNA Earnings: Beat Rate and Next Report

    Beat rate
    0 of 8 quarters (0.0%)
    Average surprise
    -129.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-3.84
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About ERNA

    Does ERNA pay dividends?

    Eterna Therapeutics Inc (ERNA) does not currently pay a regular dividend.

    What is ERNA's market cap?

    Eterna Therapeutics Inc (ERNA) has a market capitalization of $3.44M with a current stock price of $2.17.

    Related stocks

    Sector: Healthcare

    All stocks starting with E

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In